🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Starting soon! Join Julia Carnevale, John Haanen and me at 12:30 in the Tangerine Ballroom at #AACR23 to hear about Cell Therapies for the Treatment of Cancer. Memorial Sloan Kettering Cancer Center Gladstone Institutes The Netherlands Cancer Institute MSKCC | Parker Institute for Cancer Immunotherapy Parker Institute for Cancer Immunotherapy

🔎#NowHiring: A fully funded CRIS Excellence postdoctoral position for 5 years is offered to join the research group led by Miguel Fernández de Sanmamed at Cima Universidad de Navarra and Clínica Universidad de Navarra cima.cun.es/en/work-with-us

"This grant is meaningful to me because it allows me to continue my research which is focused on novel immunotherapies for rare pediatric cancers," shares CRI-Bristol Myers Squibb Fellow Dr. Lauren Banks of Memorial Sloan Kettering Cancer Center. Learn more: bit.ly/3LFpFwv #CancerResearch

📢OFERTA #empleo 🚨 Plaza abierta de #Bioinformático 🖥 en el laboratorio de Inmunoterapia traslacional🧬 del Ignacio Melero en el 📍Cima Universidad de Navarra Interesados enviar CV 📩 [email protected]. Retweet por favor.

Thrilled to share our preprint, now available on bioRxiv, revealing tumor-wide public neoantigens derived from splicing! We believe this new class of cancer targets can address intratumoral heterogeneity challenges facing immunotherapy. Okada Lab @ UCSF biorxiv.org/content/10.110…

🚨🧬💉Everything you wanted to know about TCR therapies* (*but were afraid to ask). Check out our new review in Nature Reviews Drug Discovery 👇. A wonderful collaboration between Klebanoff_Lab, @ND_BakerLab, Quezada Lab, and Toni Ribas. Memorial Sloan Kettering Cancer Center Parker Institute for Cancer Immunotherapy rdcu.be/dpCtp

Our review on T cell receptor (TCR) therapeutics takes the cover of this month’s issue of Nature Reviews Drug Discovery! Amazing art by S. Harris. Want to learn more? 👇🏻 nature.com/articles/s4157…

Dr. Christopher Klebanoff is developing a new type of immunotherapy called T cell receptor (#TCR) therapy that could one day treat more types of cancers. “Having worked on this for 20 years, I believe in the potential of this type of immunotherapy." More👇 bit.ly/48zAnwH

🎙Ep. 4 of From Bench to Fireside™ #podcast ft. #PICINetwork Investigator Memorial Sloan Kettering Cancer Center Chris Klebanoff, MD Klebanoff_Lab w/ John Connolly. They explore #Tcell activation, #bloodcancers, improving #canceroutcomes and the history of #immunotherapy➡️spoti.fi/3HsMlwJ

🚨Pre-print alert: Here, we show that CAR-T *and* CAR-NK persistence is negatively self-regulated through activation dependent FAS ligand expression. Further highlights FAS as an actionable molecule to enhance cell therapies. Parker Institute for Cancer Immunotherapy Memorial Sloan Kettering Cancer Center biorxiv.org/content/10.110…

Sarcoma oncologist Dr. Lauren Banks shares thoughts on her first #AACR24: "It's been fun to meet colleagues - some of whom are at MSK, some from around the world - who work on this disease that I probably wouldn't have been able to meet." Her research: bit.ly/4aF2UTb

Research fellow Fei Yi of Klebanoff_Lab discusses his Poster research “Persistence but not antitumor efficacy of CAR-engineered lymphocytes is governed by a FAS/FAS ligand auto-regulatory circuit” yesterday with attendees at #AACR24. Learn more: bit.ly/3PS2ksw

FAS signalling pathway is crucial for CAR T cell persistence dlvr.it/T63K9z

🚨An entire meeting dedicated to innovation and progress in solid tumor cell therapy!🚨 On behalf of my co-organizers and Society for Immunotherapy of Cancer, please save the date and spread the word! #ChristineBrown Jennifer Guerriero, PhD John Haanen Daniel Powell Lab @ UPENN Evan Weber #TIL #TCR #CAR #Synbio

#MRFResearchWednesday -- “Our research explores CD4+ T cells as a treatment option for melanoma, particularly for patients resistant to current immunotherapies. By defining factors that control how CD4+ T cells engage melanoma, we aim to identify novel pathways that may be

🚨New paper alert: Next-Generation Sequencing for HLA Genotype Screening and Matching to HLA-Restricted Therapies jamanetwork.com/journals/jamao…. Mike V. Gormally, MD PhD Adam J. Schoenfeld MSK Department of Medicine

🚨New paper alert! In collaboration with the @ND_BakerLab, we uncover the molecular mechanisms that enable TCR specificity for a PI3Ka public neoantigen over its wild-type counterpart. Memorial Sloan Kettering Cancer Center University of Notre Dame Parker Institute for Cancer Immunotherapy #Tcellpower #openaccess rdcu.be/d6W1n.

🚨Today in nature, we show that mRNA mis-splicing creates clonal public neoantigens in solid cancers. An amazing collaboration between UCSF Helen Diller Family Comprehensive Cancer Ctr and Memorial Sloan Kettering Cancer Center driven by Darwin Kwok and co-led by Hideho Okada, Joe Costello and Klebanoff_Lab. nature.com/articles/s4158…

🚨Today in Cell, we show that RNA splicing factor mutations in myeloid cancers generate splicing-derived public neoantigens targetable by #TCR tx. Amazing collaboration co-led by Abdel-Wahab Lab, Robert K. Bradley, and Klebanoff_Lab. #Tcellpower cell.com/cell/fulltext/…

🚨 Postdoctoral Position in Immuno-Oncology Join Prof. Ignacio Melero’s lab at 📍University of Oxford 🔗 Apply via University of Oxford: goo.su/1E1Za5 🔗 LinkedIn post: goo.su/l7Tin 📅 Deadline: May 22, 2025 #Immunology #Immunotherapy #Oncology #ImmunoOncology!